Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
06/30/2013 Phase 2 trial of elagolix in the treatment of uterine fibroids is expected to be completed in 1H 2013.
06/30/2013 Data from Phase 2b trial of NBI-98854 in tardive dyskinesia patients due 2Q 2013 (Kinect 1 Study).
06/30/2013 Data from second Phase 2b trial of NBI-98854 in tardive dyskinesia patients due mid 2013 (Kinect 2 Study).